Apellis Pharmaceuticals, Inc.APLSEarnings & Financial Report
Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted therapies that modulate the complement system to address serious unmet medical needs. Its core products target ophthalmic conditions like geographic atrophy secondary to age-related macular degeneration, as well as rare hematological and autoimmune disorders, with primary operations in the United States and European markets.
Revenue
$166.8M
Gross Profit
N/A
Operating Profit
$-83.3M
Net Profit
$-92.2M
Gross Margin
N/A
Operating Margin
-50.0%
Net Margin
-55.3%
YoY Growth
-3.2%
EPS
$-0.74
Apellis Pharmaceuticals, Inc. Q1 FY2025 Financial Summary
Apellis Pharmaceuticals, Inc. reported revenue of $166.8M (down 3.2% YoY) for Q1 FY2025, with a net profit of $-92.2M (down 38.8% YoY) (-55.3% margin).
Key Financial Metrics
| Total Revenue | $166.8M |
|---|---|
| Net Profit | $-92.2M |
| Gross Margin | N/A |
| Operating Margin | -50.0% |
| Report Period | Q1 FY2025 |
Revenue Breakdown
Apellis Pharmaceuticals, Inc. Q1 FY2025 revenue of $166.8M breaks down across 3 segments, led by Syfovre at $130.2M (78.0% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Syfovre | $130.2M | 78.0% |
| Empaveli Pegcetacoplan | $19.7M | 11.8% |
| Licensing And Other Revenue | $16.9M | 10.1% |
Apellis Pharmaceuticals, Inc. Revenue by Segment — Quarterly Trend
Apellis Pharmaceuticals, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Syfovre and Empaveli Pegcetacoplan) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Syfovre | $155.2M | $150.9M | $150.6M | $130.2M |
| Empaveli Pegcetacoplan | $35.1M | $26.8M | $20.8M | $19.7M |
| Licensing And Other Revenue | $9.6M | $280.8M | $7.1M | $16.9M |
Apellis Pharmaceuticals, Inc. Annual Revenue by Year
Apellis Pharmaceuticals, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $1.0B).
| Year | Annual Revenue |
|---|---|
| 2025 | $1.0B |
| 2024 | $781.4M |
Apellis Pharmaceuticals, Inc. Quarterly Revenue & Net Profit History
Apellis Pharmaceuticals, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $199.9M | -5.9% | $-59.0M | -29.5% |
| Q3 FY2025 | $458.6M | +133.0% | $215.7M | 47.0% |
| Q2 FY2025 | $178.5M | -10.6% | $-42.2M | -23.6% |
| Q1 FY2025 | $166.8M | -3.2% | $-92.2M | -55.3% |
| Q4 FY2024 | $212.5M | +45.2% | $-36.4M | -17.1% |
| Q3 FY2024 | $196.8M | +78.3% | $-57.4M | -29.2% |
| Q2 FY2024 | $199.7M | +110.3% | $-37.7M | -18.9% |
| Q1 FY2024 | $172.3M | +284.3% | $-66.4M | -38.5% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $172.3M | $199.7M | $196.8M | $212.5M | $166.8M | $178.5M | $458.6M | $199.9M |
| YoY Growth | 284.3% | 110.3% | 78.3% | 45.2% | -3.2% | -10.6% | 133.0% | -5.9% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $831.9M | $904.5M | $901.9M | $885.1M | $807.3M | $821.4M | $1.06B | $1.08B |
| Liabilities | $565.3M | $640.2M | $664.7M | $656.5M | $643.1M | $665.1M | $657.6M | $705.1M |
| Equity | $266.7M | $264.3M | $237.1M | $228.5M | $164.2M | $156.3M | $401.2M | $370.1M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-133.0M | $-8.3M | $34.1M | $19.4M | $-53.4M | $4.4M | $108.5M | $-14.2M |